Browse Subject Areas

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

< Back to Article

The risks of hepatocellular carcinoma development after HCV eradication are similar between patients treated with peg-interferon plus ribavirin and direct-acting antiviral therapy

Fig 1

Cumulative hepatocellular carcinoma (HCC) development.

Patients who achieved viral eradication by peg-interferon and ribavirin (PEG-IFN/RBV) or daclatasvir plus asunaprevir (DCV/ASV) therapies were analyzed.

Fig 1